About tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like
tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like (DUS4L) is a protein
from Homo sapiens identified by UniProt accession
O95620, 317 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like |
| UniProt accession | O95620 |
| Gene | DUS4L |
| Organism | Homo sapiens |
| Length | 317 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- COG5-congenital disorder of glycosylation · score 0.45
- neurodegenerative disease · score 0.29
- coronary artery disease · score 0.14
- congenital disorder of glycosylation · score 0.12
- alkaline phosphatase measurement · score 0.11
- hemoglobin A1 measurement · score 0.07
- low density lipoprotein cholesterol measurement · score 0.07
- vitamin D measurement · score 0.07
- electrocardiography · score 0.06
- lung adenocarcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95620-F1 | alphafold | PREDICTED | 94.39 | — |
Amino-acid sequence (317 residues)
MKSDCMQTTI CQERKKDPIE MFHSGQLVKV CAPMVRYSKL AFRTLVRKYS CDLCYTPMIV AADFVKSIKA RDSEFTTNQG DCPLIVQFAA NDARLLSDAA RIVCPYANGI DINCGCPQRW AMAEGYGACL INKPELVQDM VKQVRNQVET PGFSVSIKIR IHDDLKRTVD LCQKAEATGV SWITVHGRTA EERHQPVHYD SIKIIKENMS IPVIANGDIR SLKEAENVWR ITGTDGVMVA RGLLANPAMF AGYEETPLKC IWDWVDIALE LGTPYMCFHQ HLMYMMEKIT SRQEKRVFNA LSSTSAIIDY LTDHYGI
Explore tRNA-dihydrouridine(20a/20b) synthase [NAD(P)+]-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets